Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide written informed consent~2. Diagnosis of ITP in adult patients (≥ 18 years of age) with an insufficient response to steroids ± immunoglobulins and requiring a change in therapy~3. For Cohort 1, intent to initiate fostamatinib at enrollment as change in therapy~4. For Cohort 2, currently undergoing treatment with fostamatinib as second line therapy for at least 12 weeks, with the intent to continue, at the time of enrollment~Exclusion Criteria:~1. Any prior ITP therapy/treatment other than steroids ± immunoglobulins (e.g. rituximab, thrombopoietin receptor agonists (TPO), splenectomy)~2. Participation in any interventional study during the course of this study~3. Lack of historical platelet counts, at time of fostamatinib initiation for those entering Cohort 2~4. Pregnant and/or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Initiating treatment with fostamatinib as second-line therapy (Type: None): None
- Treated with fostamatinib for at least 12 weeks as second-line therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).